Introduction
The management of the critically ill patient in the ICU is challenging, particularly with regard to the prevention, diagnosis, and treatment of venous thromboembolism (VTE). VTE has been described as the 'last frontier for prophylaxis' 1 due to the complexity of the condition of most severely ill patients and because of their high risk of both pulmonary embolism (PE) and bleeding complications. 2, 3 Early thromboprophylaxis is desirable for critically ill patients, as more than 70% of embolic events occur during the ICU stay and their occurrence peaks during the first 4-7 days after admission. 4, 5 This early occurrence of events supports the use of prophylactic measures as soon as possible and in particular during the time frame in which the patients are most critical, and have the highest risk of bleeding or contraindications to the use of anticoagulation. Nevertheless, even though multiple studies demonstrate a significant reduction in the incidence of embolic events with the use of prophylactic anticoagulation, and even though multiple international guidelines recommend such use, the results of recent studies show that more than 30% of patients at highest risk of both PE and bleeding do not receive any thromboprophylaxis. 6, 7 Currently, a clinical diagnosis of PE is made for approximately 4% to 6% of critically ill patients, 5, 8, 9 and the occurrence of PE is confirmed by autopsy for 13% of patients who die in the ICU, despite the use of prophylactic measures. 9, 10 The available alternatives for the prevention of PE in patients for whom anticoagulation is contraindicated are limited to mechanical thromboprophylaxis with compression stockings and inferior vena cava (IVC) filters. Few or no existing randomised studies have compared the outcomes achieved with these available alternatives to the outcomes achieved by anticoagulation; thus, the benefit of these alternatives for critically ill patients has not been clearly demonstrated. The effectiveness of mechanical thromboprophylaxis with antiembolic stockings or pneumatic compression has been called into question by the Clots in Legs or Stockings after Stroke Trials and by the American College of Physicians' Clinical Practice Guidelines for the Prevention of VTE in Hospitalised Patients. 11 IVC filters are approved for patients with VTE and contraindications to anticoagulation, but they are more commonly used prophylactically. Clinical evidence for the use of filters is lacking, and their general use is not recommended. 12 The reported frequency of clinically significant PE in patients with IVC filters is relatively low (1.1-1.3%) and comparable to rates achieved with anticoagulation. 13, 14 The primary clinical problem with the use of IVC filters is related to the associated temporarily high risk of PE and to their long-term use. 13 Retrievable filters have been designed to offer the possibility of removing the IVC filter once the risk of PE has decreased or the patient can receive anticoagulation therapy. Despite this clinical advantage, most IVC filters are not removed; retrieval rates range from 12-45%. 13 
Device objectives and description
The Angel Catheter was developed as an alternative for critically ill patients at high risk of PE for whom the use of anticoagulation is temporarily or absolutely contraindicated. It combines the features of an IVC filter and a central venous catheter (CVC). It is intended for bedside placement with standard venous access techniques and/or ultrasound guidance, and can be removed (IVC filter is permanently attached to the CVC) once the risk of PE has decreased or prophylactic anticoagulation can be initiated.
The Angel Catheter (Figure 1) consists of a self-expanding Nitinol filter permanently attached to a multilumen CVC and is designed for femoral venous access only. The filter is deployed through an attached sheath (length, 35 cm; outer diameter, 9F) that is placed intravenously over a 0.035-in guidewire, and the sheath remains in place until the filter is removed. The catheter component is a triple-lumen CVC with ports proximal to, within, and distal to the filter. Both the sheath and the catheter are made of polyether block amide (PEBAX ® ) resins and are flexible and kink-resistant. The filter has a self-centering closed design without barbs or hooks. It is secured in place by the catheter and is recaptured by withdrawal into the 9F sheath.
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Pulmonary embolism (PE) is a serious complication among critically ill patients. Despite the recommended and effective use of prophylactic anticoagulation, new options are required, particularly for critically ill patients with absolute or temporary contraindications to the use of anticoagulation. The Angel ® Catheter (BiO 2 Medical, Inc. San Antonio, Texas) is intended for these critically ill patients, allowing early PE prophylaxis without additional bleeding risk. The device is inserted at the bedside, provides both central venous access and inferior vena cava filtration, and can be successfully removed in all instances. Clinical experience and ongoing research will help define the role of the Angel Catheter in PE prophylaxis for critically ill patients. 
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Clinical experience
The first in-man pilot clinical trial was conducted to assess the safety of the device for severely ill medical and surgical patients at increased risk of PE. 15 This pilot trial enrolled eight critically ill medical and surgical patients considered at high risk of PE who were not candidates for medical thromboprophylaxis. The average age was 35 years old. Six of the eight patients had experienced major trauma, and at the time of insertion three patients had active bleeding and one had a PE. All of the filters were inserted at the bedside without placement-related complications. No repositioning of the device was required for any patient. All eight study devices were retrieved without complications, with a mean time to catheter retrieval of four days. In one patient a large clot was trapped by the Angel Catheter (Figure 2) ; the device was retrieved without complications after placement of a traditional retrievable IVC filter and initiation of anticoagulation. No new PEs, major bleeding, or catheter-related bloodstream infections or deep venous thromboses (DVTs) occurred in any of the patients during the study period.
Opportunities for enhanced PE prevention
VTE is considered the leading cause of preventable hospital death. Greater and more consistent use of anticoagulation therapy as the standard of care for ICU patients is effective in preventing a significant number of PE events. However, there is a portion of underserved patients who are vulnerable to VTE and for whom the current standard of care may not be suitable. These include, but are not limited to, patients with haemorrhagic stroke, GI bleeds or liver lacerations, neurovascular trauma, hepatic insufficiency, coagulopathy, patients allergic to anticoagulants, and postorthopaedic surgery patients. Anticoagulation is contraindicated for many in these patient groups, either initially upon admission to the ICU or for the full duration of their ICU or hospital stay. The Angel Catheter has been designed to protect patients at high risk for PE not protected by current standards of care.
Conclusions
New alternatives for early PE prophylaxis are necessary for critically ill patients for whom well-studied anticoagulation options are contraindicated. IVC filters are effective in preventing PE but are not commonly used because their insertion is commonly delayed and complex for critically ill patients and their use is associated with long-term complications. The Angel Catheter is intended for this critically ill population.
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